Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A histopathologic term for a pattern of diseases characterized by extensive crescent formation in the glomeruli; patients present clinically with rapid deterioration of renal function, and possible progression to end-stage renal failure within weeks or months.
Biomarker and diagnostic research for crescentic glomerulonephritis has been reported in the published literature.
2 clinical trials registered, 2 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE3. Research is primarily sponsored by academic and government institutions.
244 publications have been identified in PubMed for crescentic glomerulonephritis. Kisho has analyzed 109 by research type. Research spans Case Report / Case Series (48%), Review / Meta-Analysis (17%), and Epidemiology / Natural History (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 52 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 7:47 AM UTC
48%
Research summaries | 18 | 17% |
Disease patterns and progression | 14 | 13% |
Laboratory research | 12 | 11% |
Other research | 5 | 5% |
Testing and diagnosis research | 5 | 5% |
New treatment approaches | 2 | 2% |
Clinical study results | 1 | 1% |
Yılmaz T (2026). [PMID: 41706424](https://pubmed.ncbi.nlm.nih.gov/41706424/). *Acta Clin Belg*. [Epidemiology / Natural History]
Kyhan ME (2026). [PMID: 42107047](https://pubmed.ncbi.nlm.nih.gov/42107047/). *Am J Case Rep*. [Case Report / Case Series]
Yin J (2026). [PMID: 41762738](https://pubmed.ncbi.nlm.nih.gov/41762738/). *Adv Sci (Weinh)*. [Basic Science / Preclinical]
İçaçan G (2026). [PMID: 41928069](https://pubmed.ncbi.nlm.nih.gov/41928069/). *BMC Nephrol*. [Case Report / Case Series]
Scoglio M (2026). [PMID: 41330036](https://pubmed.ncbi.nlm.nih.gov/41330036/). *J Autoimmun*. [Review / Meta-Analysis]
Shah T (2026). [PMID: 41988540](https://pubmed.ncbi.nlm.nih.gov/41988540/). *Eur J Case Rep Intern Med*. [Case Report / Case Series]
Charkviani M (2026). [PMID: 42222441](https://pubmed.ncbi.nlm.nih.gov/42222441/). *Kidney Med*. [Case Report / Case Series]
Yıldırım S (2026). [PMID: 41719207](https://pubmed.ncbi.nlm.nih.gov/41719207/). *Nephron*. [Diagnostic / Biomarker]
Şahin H (2026). [PMID: 41777676](https://pubmed.ncbi.nlm.nih.gov/41777676/). *Int J Gen Med*. [Diagnostic / Biomarker]
Furuyama R (2026). [PMID: 41484332](https://pubmed.ncbi.nlm.nih.gov/41484332/). *CEN Case Rep*. [Case Report / Case Series]
AI-curated news mentioning crescentic glomerulonephritis
Updated Mar 5, 2013
The CDC highlights the rising threat of carbapenem-resistant Enterobacteriaceae (CRE) in U.S. healthcare settings, emphasizing the urgent need for awareness and action among patients and healthcare providers. This drug-resistant bacteria poses significant risks, leading to life-threatening infections that are increasingly difficult to treat.